Home › Heart Failure › NCT00762008
Circulating Markers That Underlie the Transition From Compensated Hypertrophy to Heart Failure
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Individuals aged \>18yrs * stable or decompensated heart failure, irrespective of LVEF * decompensated heart failure clinical symptoms such as dyspnea, rales, edema, elevated jugular venous pressure, or ascites * Imaging evidence of heart failure (cardiomegaly, poor contractile function or echocardiographic Doppler evidence of diastolic dysfunction or elevated right- or left-sided filling pressures) * Healthy individuals with no prior history of heart attack or heart failure will be recruited to use as controls. Exclusion Criteria: * Subjects who are unable to give informed consent * Subjects who had undergone cardiac or non-cardiac surgery in the 3 months before enrollment * Pregnant subjects are not excluded
About the study
The purpose of this research is to determine if two proteins in the blood are increased during acute heart failure. These two proteins are produced when the heart becomes dysfunctional and unable to contract normally. They may then be released into the blood and be detected by standard method in the research laboratory. Thus, the purpose of this study is to determine the relation between the change of these two proteins in the blood and the occurrence of acute heart failure. At this time, detection of an increase in these proteins in the blood is not known to be associated with any disease or heart failure.
Sponsor: UConn Health · Participants: 500 · Started: 2005-12
Contact the study team
- Kristen Siedlarz, MA · Phone: 860-679-7549
Official record on ClinicalTrials.gov — NCT00762008
Locations in the U.S.
| Connecticut | University of Connecticut Health Center, Farmington |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.